Triple-negative (ER-negative, PR-negative, HER2/neu not overexpressed) breast cancer has distinct clinical and pathologic features, and is a clinical problem because of its relatively poor prognosis, aggressive behaviour and lack of targeted therapies, leaving chemotherapy as the mainstay of treatment...
TNBC, triple-negative breast cancer; PARP, poly-ADP-ribose-polymerase; ORR, overall response rate; PFS, progression-free survival; OS, overall survival; VEGF, vascular endothelial growth factor; ER, estrogen receptor; PgR, progesterone receptor; RR, response rate; EGFR, epidermal growth factor rec...
晚期乳腺癌患者是“历史上被忽视的群体”,一个叫Advanced Breast Cancer Group的学术组织这么说,也有制药企业这样定义ABC,“a story of half told”.总体就一个意思,加强对晚期乳腺癌患者人群的关注,无论从临床实践和新药研发。 晚期乳腺癌大体上分为...
Triple negative breast cancer is more often responsive to chemotherapy than hormone receptor positive (ER+/PR+) breast cancer. On the other hand, long-term hormonal treatments (tamoxifen, aromatase inhibitors) used for ER+ subtypes are not effective for triple negative breast cancer since estrogen ...
Fig. 1: Intrinsic molecular subtypes of breast cancer. Within each clinical subtype there are multiple molecular subtypes. ER endocrine receptor; TNBC triple negative breast cancer; HER2 Human Epidermal Growth Factor Receptor 2. Full size image ...
对于ER、PR、HER2均阴性乳腺,目前称为受体三阴性乳腺癌(Triple negative breast cancer),其对内分泌治疗及抗HER2的靶 … www.haodf.com|基于7个网页 2. 三阴性乳腺癌病人 还记得刚诊断乳腺癌时查生存率,得知象我这种三阴性乳腺癌病人(Triple negative breast cancer)来说前三年是个坎,癌症复发 … ...
If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite several efforts, transcriptomic and genomic classifications have remained merely
The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancerYu, K.-D.; Shen, Z.-Z.; Shao, Z.-M.Breast Cancer Research and Treatment 118(3): 661-663...
Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast cancer that lacks the expression of oestrogen receptors, progesterone receptors and human epidermal growth factor receptor 2. Although TNBC is sensitive to chemotherapy, the